Skip to main content
Premium Trial:

Request an Annual Quote

SoluLink Pockets $300K in VC Cash to Continue Marketing Its Biomolecule Conjugation Technology

NEW YORK (GenomeWeb News) — Bioconjugation product developer SoluLink today reported it has received $300,000 in venture capital from Plymouth Venture Partners.
 
SoluLink President Steve DeGraw said the investment will enable the company to continue marketing existing products, and to integrate them into new markets.
 
DeGraw also said the company is planning a public rollout of its products this fall in the form of a catalog and trade show appearances, and hopes to secure more financing in the near future.
 
This is Plymouth’s first funding agreement with San Diego-based SoluLink.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.